Form of Vitamin D: some need fatty meals, some respond quickly, etc.

Vitamin D Forms Comparison

^{†"Bioavailability" = intestinal absorption into lymph/portal circulation relative to maximum achievable — not serum 25(OH)D increase, which depends on additional metabolic steps.}

Form	Bioavail. without fat^†	Bioavail. with fat^†	Time to peak response	Acute-care suitability
Plain vitamin D _{D3 oil/powder capsule}	Low ¹	High ²	25(OH)D peaks ~7 days after single dose; full plateau after ~3 months of daily dosing ³	Not suitable _{Weeks-scale response too slow for acute needs}
Water-dispersible D3 _{Micellar / emulsified D3}	Moderate ⁴	High ⁴	Similar curve to plain D3; fat-independence is the key advantage; same weeks-to-months timeline ⁵	Limited _{Useful for fat malabsorption; still too slow for true acute care}
Liposomal vitamin D _{Phospholipid vesicles}	High ⁶	High ⁶	Faster initial absorption vs. plain D3; 25(OH)D rise measurable within 1–3 days of loading; still weeks to full plateau ⁷	Limited _{Best fat-independent oral option; days-scale, not hours}
Calcifediol _{25(OH)D — storage form (Rx in some countries)}	High ⁸	High ⁸	Serum 25(OH)D rises within 4–8 h of a loading dose; bypasses hepatic 25-hydroxylation step ⁹	Good _{Hours-scale response; preferred oral agent for ICU loading (e.g. SCCM protocols, COVID-19 trials) ¹⁰}
Calcitriol _{1,25(OH)₂D — active form (Rx)}	High ¹¹	High ¹¹	Biological effect within hours; peaks ~3–6 h post-dose; half-life only ~5–8 h — effects are short-lived ¹²	Ideal — with caution _{Fastest VDR activation; IV form available; narrow therapeutic window — hypercalcemia risk ¹³}

Notes

Oil-based capsules depend heavily on co-ingested fat; absorption can drop 30–50% fasted.
Taken with ≥10 g fat, absorption approaches liposomal levels.
25(OH)D half-life ≈ 2–3 weeks; plateau reflects steady-state accumulation.
Micellar/emulsified forms are pre-solubilized; ~30–40% higher absorption fasted vs. plain oil; gap largely closes with fat.
No robust RCT evidence of faster 25(OH)D rise vs. plain D3 at equivalent doses once fat intake is controlled.
Phospholipid envelope enables direct lymphatic uptake; partially bypasses gut metabolism; fat-independent.
Early-rise data from small studies; clinical significance vs. plain D3 at therapeutic doses not yet fully established.
Calcifediol (Rayaldee, Hidroferol) is already 25-hydroxylated — absorbed like any fat-soluble molecule and does not require hepatic conversion.
Bypassing the liver's CYP2R1/CYP27A1 step is the key pharmacokinetic advantage over cholecalciferol in acute settings.
Used in the Castillo et al. COVID-19 RCT (Córdoba); also the form recommended by some SCCM vitamin D working group discussions for rapid ICU repletion. Soft-gel formulation (Hidroferol) achieves faster peak than extended-release Rayaldee.
Calcitriol is a small lipophilic molecule; also available as IV formulation for critical care bypass of all conversion steps.
Short half-life makes calcitriol unsuitable for rebuilding 25(OH)D stores; acts directly on VDR without CYP27B1 activation.
Hypercalcemia risk is significant with calcitriol — calcium and phosphate monitoring required. Best reserved for renal failure patients (who cannot activate calcifediol) or true emergencies where speed outweighs risk.
Soft-gel Hidroferol formulation (widely available in Spain, used in the Castillo COVID trial) achieves a faster peak than the extended-release Rayaldee capsule approved in the US — same molecule, very different pharmacokinetics.

The above was made by Claude AI, May 2026

Related in VitaminDWiki

Getting Vitamin D into your blood and cells has the following chart

Calcitriol

Liposomal (used by vitaminDWiki, very low cost)

Nanoemulsion (swish in mouth for fast response)

Gut-Friendly

Inhaled (response in < 10 minutes?. especially good for lungs and nose